Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of (FMS)
23.55
-0.17 (-0.72%)
Fresenius Medical Care is a global leader in providing products and services for individuals with kidney disorders, particularly those requiring dialysis
The company operates a vast network of dialysis clinics and offers a range of medical devices and equipment used in kidney care treatment. In addition to its clinical services, Fresenius Medical Care is also involved in the research and development of innovative therapies and solutions to improve the quality of life for patients with chronic kidney disease, focusing on enhancing patient outcomes through comprehensive care and support.
Fresenius Medical Care (FMS) is the largest dialysis company in the world. Over the past year, Fresenius's share price fell just over 30% from $26.09 to $18.14 as of Monday’s market close.
Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022.
Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite holding a 32% stake, challenges like high dialysis patient mortality and nursing shortages impact both companies' performance and share value.
Fresenius Medical Care is the largest dialysis company in the world and a leading supplier of dialysis products, including machines, dialyzers, and concentrates.
Novo Nordisk's FLOW trial reveals a 24% reduction in kidney disease progression, cardiovascular events, and death with semaglutide 1.0 mg compared to placebo. Impact on dialysis stocks
Shares of SOPHiA GENETICS SA (NASDAQSOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
